诱导自身免疫性糖尿病耐受的生物工程策略。
Bioengineering strategies for inducing tolerance in autoimmune diabetes.
机构信息
Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Building SV 3826, Station 19, CH-1015 Lausanne, Switzerland; Departments of Medicine and Microbiology/Immunology, Diabetes Center, 513 Parnassus Ave, 20159, Box 0534, University of California San Francisco, San Francisco, CA, 94143, USA.
Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Building SV 3826, Station 19, CH-1015 Lausanne, Switzerland; Institute for Molecular Engineering, University of Chicago, 5640 S Ellis Avenue, Chicago, IL 60615, USA.
出版信息
Adv Drug Deliv Rev. 2017 May 15;114:256-265. doi: 10.1016/j.addr.2017.06.007. Epub 2017 Jun 15.
Type 1 diabetes is an autoimmune disease marked by the destruction of insulin-producing beta cells in the pancreatic islets. Strategies to delay onset or prevent the autoimmune recognition of beta cell antigens or T cell-mediated killing of beta cells have mainly focused on systemic immunomodulation and antigen-specific immunotherapy. To bridge the fields of type 1 diabetes immunology and biomaterials engineering, this article will review recent trends in the etiology of type 1 diabetes immunopathology and will focus on the contributions of emerging bioengineered strategies in the fight against beta cell autoimmunity in type 1 diabetes.
1 型糖尿病是一种自身免疫性疾病，其特征是胰腺胰岛中产生胰岛素的β细胞被破坏。延迟发病或预防β细胞抗原的自身免疫识别或 T 细胞介导的β细胞杀伤的策略主要集中在全身免疫调节和抗原特异性免疫治疗上。为了弥合 1 型糖尿病免疫学和生物材料工程领域之间的差距，本文将回顾 1 型糖尿病免疫病理学病因的最新趋势，并重点介绍新兴的生物工程策略在对抗 1 型糖尿病β细胞自身免疫中的贡献。
Zotero 插件